pk 11195 has been researched along with Multiple Myeloma in 1 studies
PK-11195 : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 1-(2-chlorophenyl)isoquinoline-3-carboxylic acid with the amino group of sec-butylmethylamine
Multiple Myeloma: A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Bortezomib (PS-341), a selective inhibitor of proteasomes, induces apoptosis in multiple myeloma (MM) cells; however, prolonged drug exposure may result in cumulative toxicity and the development of chemoresistance." | 7.72 | Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells. ( Anderson, KC; Chauhan, D; Cotter, FE; Hideshima, T; Li, G; Mitsiades, C; Munshi, N; Podar, K; Richardson, P; Schlossman, R, 2004) |
| "Bortezomib (PS-341), a selective inhibitor of proteasomes, induces apoptosis in multiple myeloma (MM) cells; however, prolonged drug exposure may result in cumulative toxicity and the development of chemoresistance." | 3.72 | Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells. ( Anderson, KC; Chauhan, D; Cotter, FE; Hideshima, T; Li, G; Mitsiades, C; Munshi, N; Podar, K; Richardson, P; Schlossman, R, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chauhan, D | 1 |
| Li, G | 1 |
| Podar, K | 1 |
| Hideshima, T | 1 |
| Mitsiades, C | 1 |
| Schlossman, R | 1 |
| Munshi, N | 1 |
| Richardson, P | 1 |
| Cotter, FE | 1 |
| Anderson, KC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma[NCT00461045] | Phase 2 | 15 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Duration of treatment is defined as the last dose date minus the first dose date of the dose cohort plus 1 expressed in weeks. (NCT00461045)
Timeframe: Through study completion, an average of 6.09 weeks.
| Intervention | weeks (Mean) |
|---|---|
| MRZ 0.5 mg/m^2 | 6.09 |
(NCT00461045)
Timeframe: Through study completion, an average of 6.09 weeks.
| Intervention | cycles (Mean) |
|---|---|
| MRZ 0.5 mg/m^2 | 2.6 |
Disease response and progression were determined by the investigator using the International Myeloma Working Group Uniform Response Criteria (IMWG-URC). Overall response rate includes patients with a best response of PR of better. Stringent complete response (CR) includes immunophenotypic CR and molecular CR in addition to stringent CR. (NCT00461045)
Timeframe: Through study completion, an average of 6.09 weeks.
| Intervention | participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Stringent Complete Response (sCR) or better | Complete Response (CR) | Very Good Partial Response (VGPR) | Partial Response (PR) | Minimal Response (MR) | Stable Disease (SD) | Progressive Disease (PD) | Not Evaluated | |
| MRZ 0.5 mg/m^2 | 0 | 0 | 0 | 0 | 0 | 4 | 9 | 2 |
A patient was counted in a cycle if the patient received at least one dose of study drug during the cycle. (NCT00461045)
Timeframe: Through study completion, an average of 6.09 weeks.
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| Cycle 1 | Cycle 2 | Cycle 3 | Cycle 4 | Cycle 5 | Cycle 6 | |
| MRZ 0.5 mg/m^2 | 15 | 12 | 6 | 3 | 2 | 1 |
"Adverse events were graded using NCI-CTCAE (version 4.3). TEAEs are defined as any adverse event with an onset date between the date of first dose and 30 days after the date of last dose of any study drug.~Treatment-related adverse events are adverse events considered related to at least one study drug by the investigator (NPI-002, dexamethasone), including those with unknown relationship." (NCT00461045)
Timeframe: Through study completion, an average of 6.09 weeks.
| Intervention | Participants (Count of Participants) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| At least one TEAE | At least one treatment related TEAE | At least one NPI-0052 related TEAE | At least one grade ≥3 TEAE | At least one treatment related grade ≥3 TEAE | At least one NPI-0052 related grade ≥3 TEAE | At least one serious TEAE | At least one treatment related serious TEAE | At least one NPI-0052 related serious TEAE | |
| MRZ 0.5 mg/m^2 | 15 | 14 | 13 | 12 | 8 | 5 | 7 | 4 | 1 |
"Adverse events were graded using NCI-CTCAE (version 4.3). TEAEs are defined as any adverse event with an onset date between the date of first dose and 30 days after the date of last dose of any study drug.~Treatment-related adverse events are adverse events considered related to at least one study drug by the investigator (NPI-002, dexamethasone), including those with unknown relationship." (NCT00461045)
Timeframe: Through study completion, an average of 6.09 weeks.
| Intervention | TEAEs (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Number of TEAEs | Number of treatment related TEAEs | Number of NPI-0052 related TEAEs | Number of grade ≥3 TEAEs | Number of treatment related grade ≥3 TEAEs | Number of NPI-0052 realted grade ≥3 TEAEs | Number of serious TEAEs | Number of treatment related serious TEAEs | Number of NPI-0052 related serious TEAEs | |
| MRZ 0.5 mg/m^2 | 149 | 73 | 50 | 41 | 16 | 9 | 21 | 5 | 1 |
1 other study available for pk 11195 and Multiple Myeloma
| Article | Year |
|---|---|
Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspases; Cell Survival; Cytochromes c; | 2004 |